Nutex Health, Inc. (NUTX) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $197.66 (-5.92%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Sep 18, 2024 | Anthony Vendetti | Maxim Group | $45.00 | -77.2% |
Top Analysts Covering NUTX
NUTX vs Sector & Market
| Metric | NUTX | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.41 |
| Analyst Count | 3 | 8 | 19 |
| Target Upside | +56.8% | +153002.0% | +21.5% |
| P/E Ratio | 15.35 | 3.46 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $221M | $239M | $264M | 2 |
| 2027-12-31 | $940M | $947M | $955M | 2 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $3.82 | $4.25 | $4.83 | 1 |
| 2027-12-31 | $16.79 | $17.55 | $18.62 | 1 |
Frequently Asked Questions
What is the analyst consensus for NUTX?
The consensus among 3 analysts covering Nutex Health, Inc. (NUTX) is Buy with an average price target of $310.00.
What is the highest price target for NUTX?
The highest price target for NUTX is $45.00, set by Anthony Vendetti at Maxim Group on 2024-09-18.
What is the lowest price target for NUTX?
The lowest price target for NUTX is $45.00, set by Anthony Vendetti at Maxim Group on 2024-09-18.
How many analysts cover NUTX?
3 analysts have issued ratings for Nutex Health, Inc. in the past 12 months.
Is NUTX a buy or sell right now?
Based on 3 analyst ratings, NUTX has a consensus rating of Buy (2.00/5) with a +56.8% upside to the consensus target of $310.00.
What are the earnings estimates for NUTX?
Analysts estimate NUTX will report EPS of $4.25 for the period ending 2026-12-31, with revenue estimated at $239M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.